Evidence map›Paper›PMID 39043879›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

In silico method and bioactivity evaluation to discover novel antimicrobial agents targeting FtsZ protein: Machine learning, virtual screening and antibacterial mechanism study.

Linxiao Wang, Zhouling Xie, Wei Ruan, Feixiang Lan, Qi Qin, Yuanbiao Tu, Wufu Zhu, Jing Zhao, Pengwu Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linxiao WangJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China. wanglinxiao542@163.com.
Zhouling XieJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Wei RuanJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Feixiang LanJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Qi QinJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Yuanbiao TuCancer Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, China.
Wufu ZhuJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Jing ZhaoJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
Pengwu ZhengJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China. zhengpw@163.com.

Funding

Jiangxi Province Science Foundation for Youths 20224BAB216112National Natural Science Foundation of China 82060629Open Foundation of Jiangxi Provincial Key Laboratory of Drug Design and Evaluation JKLDE-KF-2203Ph.D. Startup Foundation of Jiangxi Science and Technology Normal University 2021BSQD25Science and Technology Research Foundation of Jiangxi Education Department GJJ211138the Undergraduate Research Foundation of Jiangxi Science and Technology Normal University 20231704200
6 · The paper itself

Abstract

This research paper utilizes a fused-in-silico approach alongside bioactivity evaluation to identify active FtsZ inhibitors for drug discovery. Initially, ROC-guided machine learning was employed to obtain almost 13182 compounds from three libraries. After conducting virtual screening to assess the affinity of 2621 acquired compounds, cluster analysis and bonding model analysis led to the discovery of five hit compounds. Additionally, antibacterial activity assays and time-killing kinetics revealed that T3995 could eliminate Staphylococcus aureus ATCC6538 and Bacillus subtilis ATCC9732, with MIC values of 32 and 2 μg/mL. Further morphology and FtsZ polymerization assays indicated that T3995 could be an antimicrobial inhibitor by targeting FtsZ protein. Moreover, hemolytic toxicity evaluation demonstrated that T3995 is safe at or below 16 ug/mL concentration. Additionally, bonding model analysis explained how the compound T3995 can display antimicrobial activity by targeting the FtsZ protein. In conclusion, this study presents a promising FtsZ inhibitor that was discovered through a fused computer method and bioactivity evaluation.

Indexed as

Anti-Bacterial AgentsBacterial ProteinsCytoskeletal ProteinsDrug DiscoveryMachine LearningAnimalsBacillus subtilisComputer SimulationDrug Evaluation, PreclinicalHumansMicrobial Sensitivity TestsMolecular Docking SimulationStaphylococcus aureusAnti-Bacterial AgentsBacterial ProteinsCytoskeletal ProteinsFtsZ protein, BacteriaAntibacterial mechanismAntimicrobial activityFtsZ inhibitorMachine learningVirtual screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.